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Abstract
Background: Antimicrobial peptides (AMPs) are a class of antimicrobial agents with broad-spectrum activities.
Several reports indicate that cationic AMPs bind to the negatively charged bacterial membrane causing membrane
depolarization and damage. However, membrane depolarization and damage may be insufficient to elicit cell
death, thereby suggesting that other mechanism(s) of action could be involved in this phenomenon. In this study,
we investigated the antimicrobial activity of a novel antimicrobial peptide, TP359, against two strains of
Pseudomonas aeruginosa, as well as its possible mechanisms of action.
Results: TP359 proved to be bactericidal against P. aeruginosa as confirmed by the reduced bacteria counts,
membrane damage and cytoplasmic membrane depolarization. In addition, it was non-toxic to mouse J774
macrophages and human lung A549 epithelial cells. Electron microscopy analysis showed TP359 bactericidal effects
by structural changes of the bacteria from viable rod-shaped cells to those with cell membrane damages,
proceeding into the efflux of cytoplasmic contents and emergence of ghost cells. Gene expression analysis on the
effects of TP359 on outer membrane biogenesis genes underscored marked down-regulation, particularly of oprF,
which encodes a major structural and outer membrane porin (OprF) in both strains studied, indicating that the peptide
may cause deregulation of outer membrane genes and reduced structural stability which could lead to cell death.
Conclusion: Our data shows that TP359 has potent antimicrobial activity against P aeruginosa. The correlation between
membrane damage, depolarization and reduced expression of outer membrane biogenesis genes, particularly oprF
may suggest the bactericidal mechanism of action of the TP359 peptide.
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Background
With continuous usage of antibiotics overtime, patho-
genic bacteria buildup resistance, and this is a major
drawback for the treatment of a plethora of bacterial in-
fections. Hence, there is an increasing need for anti-
microbial agents with novel mechanisms of action,
which target essential cellular metabolic processes and
pathways. In order to combat recalcitrant pathogens, es-
sential targets for viability, growth and pathogenicity
must be identified [1].
Antimicrobial peptides (AMPs) are a class of antimicro-
bial agents that have been of interest, and they are consid-
ered to be a potential substitute for conventional
antibiotics [2]. AMPs are a group of bactericidal molecules
of the innate immune system in multicellular organisms
and in unicellular organisms, represses competing species
[3]. Cationic AMPs are small positively charged amphi-
pathic peptides; having both hydrophilic and hydrophobic
ends, which enable the molecules to be soluble in aqueous
medium and to penetrate lipid-rich membranes of bacter-
ial cells. It is well established that electrostatic attraction
between the positively-charged antimicrobial peptides (+2
to +9) [4] and the highly negative-charged bacterial mem-
brane enables the first step of attachment of the peptide
to the bacteria [5]. The negative charge is due to compos-
ition of the membranes of bacteria, which is different from
eukaryotic cells. This difference partially explains the sen-
sitivity of bacterial cells to AMPs and the lack of toxicity
to eukaryotic cells [6].
Although the exact mechanisms of action of AMPs are
not fully understood, several have been proposed, such
as the interaction of AMPs with membranes in the car-
pet, toroid and barrel-stave models [7] causing mem-
brane damage. Additionally, other mechanisms of action
have been attributed to the integration of AMPs into the
cytoplasmic membrane. However, membrane perturb-
ation/depolarization alone may not be sufficient to cause
cell death by cationic AMPs, as reported for gramicidin
S action against P. aeruginosa [8]. Furthermore, there is
a gap in studies addressing the interaction of AMPs with
essential genes involved in cellular metabolism and
membrane biosynthesis genes.
P. aeruginosa is a ubiquitous Gram-negative bacterium
and one of the most important clinical opportunistic path-
ogens. It is a persistent pathogen associated with nosoco-
mial infections [9], wound infections [10, 11], urinary tract
infections (UTIs) [12], otitis media, nasal infections [13]
acute and chronic lung infections in artificially ventilated
[14] and cystic fibrosis (CF) patients [15, 16]. P. aerugi-
nosa infection is difficult to eradicate completely, espe-
cially in CF patients, in whom, infection results in
decreased lung function and uncontrolled inflammation
[17, 18]. It continues to pose a therapeutic problem due to
drug resistance developing during therapy, caused by low
permeability of its outer membrane, multi-drug efflux
pumps and AmpC β-lactamases [19] resulting in high
rates of morbidity and mortality. Additionally, during the
initial colonization of P. aeruginosa, the non-mucoid
phenotype is the dominant phenotype, however, as the
infection progresses there is a switch to a more persistent
mucoid phenotype [20]. This conversion results from the
production of a large quantity of alginate [21], which is
followed by the formation of a protected biofilm of micro-
colonies [15, 22, 23], resulting in persistent infections [24],
poor prognosis of infected patients and mortality and
morbidity in CF patients. The mucoid state also enables
P. aeruginosa to elude opsonization, phagocytosis, and
digestion by host defense mechanisms [25].
In this study, the antimicrobial activity of a novel
antimicrobial peptide TP359 was investigated against a mu-
coid and a non-mucoid strain of P. aeruginosa. We assessed
its effect on membrane biogenesis, peptidoglycan-
associated genes and on essential genes of P. aeruginosa in
order to determine the possible mechanisms of action of
AMPs.
Methods
Bacterial cultures and reagents
P. aeruginosa strains ATCC 39324 and ATCC 27318
used in this study were purchased from the American
Type Culture Collection (Manassas, VA). Cation-
adjusted Mueller Hinton broth (CA-MHB; Becton
Dickson, Franklin Lakes, NJ) was used to grow the bac-
teria for determination of in-vitro antimicrobial activity
and time-kill assays. Luria-Bertani medium (LB; Becton
Dickson) was used for the membrane-depolarization
assay and quantitative real time-polymerase chain reac-
tion (qRT-PCR) analysis. Todd-Hewitt medium (Becton
Dickson) supplemented with yeast extract (THY) was
used to grow the bacteria for scanning electron micros-
copy (SEM) and transmission electron microscopy
(TEM). Gentamicin sulphate and polymyxin B were pur-
chased from Fisher Scientific (Pittsburgh, PA).
Antimicrobial peptide TP359
The proprietary antimicrobial peptide (AMP) TP359
(MYR-KKALK-[K]D-amide, C41H81N9O6) was synthesized
with > 95 % purity by Therapeutic Peptides Inc., (Baton
Rouge, LA). The structure of TP359 was predicted de
novo by converting the peptide sequence to its tertiary
structure using PEPStr; a method for tertiary structure
prediction of small bioactive peptides [26]. TP359 was one
of several proprietary AMPs from Therapeutic peptides
Inc. that was screened for antimicrobial activity against P.
aeruginosa (data not shown). TP359 showed enhanced
antimicrobial activity against P. aeruginosa and thus was
selected for further studies.
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Bactericidal assay
We evaluated the bactericidal activity of TP359 against
P. aeruginosa by first determining the minimum inhibi-
tory concentration (MIC). TP359 was serially diluted 2-
fold starting at 64 to 0 μg/mL and added into non-
treated polystyrene 96-well plates, according to the Clin-
ical and Laboratory Standards Institute (CLSI) M7-A7
method [27] as previously described [28]. Each well was
next inoculated with 20 μL (1 × 106 CFU/mL) of either
strain of P. aeruginosa in CA-MHB to a final concentra-
tion of approximately 1 × 105 CFU/mL. Bacteria alone
served as positive control to verify bacteria growth, while
negative control wells contained only media to ascertain
culture sterility. To determine the minimum bactericidal
concentration (MBCs) [29] we used TP359 at two or
three concentrations higher than its MIC. The bacteria
concentrations were then plated on Luria agar (LA)
plates and viable CFU/mL counts were enumerated by
plate count assay.
Time-kill studies
The time-kill studies of TP359 against both strains of P.
aeruginosa were performed as we recently reported [28],
according to the M26-A guidelines of the CLSI [30]. Ei-
ther P. aeruginosa strains (1 × 105 CFU/mL) were inocu-
lated into non-treated polystyrene 96-well plates
containing TP359 concentrations correlating to their re-
spective MICs (0.5×, 1×, 2×, 4× and 8× MIC). Viable cell
counts were determined after 2, 4, 8 and 24 h of incuba-
tion at 37 °C by plate count assay.
Toxicity of the peptide to eukaryotic cell lines
Cell lines used in this study were the human lung car-
cinoma epithelial A549 cell line (ATCC® CCL-185™) and
the mouse J774 macrophage cell line (ATCC® TIB-67™).
A549 was used because P. aeruginosa is known to infect
the respiratory tract of cystic fibrosis (CF) patients, while
macrophages are the first line of defense during infec-
tion. The A549 and J774 cell lines were cultured in F-
12K Medium (Life Technologies, Grand Island, NY) and
Dulbecco’s Modified Eagle Medium (DMEM, Life tech-
nologies), respectively supplemented with 10 % fetal bo-
vine serum (FBS; Life technologies) and 1 % 100×
antibiotic-antimycotic (Life technologies). The cytotoxic
effect of TP359 on cell lines (A549 and J774) was deter-
mined using the Cell-Titer 96® Non-Radioactive Cell
Proliferation assay kit (Promega G4000, Madison WI) as
previously described [31].
Membrane permeabilization assay
The effect of TP359 on outer membrane integrity of P.
aeruginosa was analyzed using the LIVE/DEAD
BaclightTM viability kit L13152 (Molecular probes, Life
Technologies) according to the manufacturer’s protocol.
Overnight cultures of bacteria were inoculated into THY
and grown at 37 °C to an optical density of 0.1 (1 ×
109 CFU/mL) before being exposed to 4× MIC for 4 h.
Negative cultures included those without added peptide.
Cultures were centrifuged at 2000 × g for 10 min,
washed, further incubated in 1 mL of 0.85 % NaCl for
1 h and then finally re-suspended in 200 μL of 0.85 %
NaCl. Bacteria cells were then incubated in the dark for
45 min in a 2X stock solution of the baclight staining re-
agent containing a final concentration of 6 μM SYTO 9
and 30 μM of propidium iodide. Images were captured
using a Nikon Eclipse TE200 microscope (Nikon,
Melville, NY, USA) using FITC-HYQ (Ex 450–500) and
TRITC HYQ (Ex 530–550) filters.
Membrane depolarization assay
Cytoplasmic membrane depolarization was determined
using the fluorescent dye 3,3-dipropylthiacarbocyanine
iodide [DiSC3(5); Fisher Scientific, Waltham MA] as
described [32] with some modifications. Exponential-
phase bacteria at approximately 1 × 109 CFU/mL in
buffer (5 mM HEPES, 5 mM glucose; pH 7.4) were
incubated in 0.4 mM DiSC3 (5). After this, KCl
(100 mM) was added to equilibrate the cytoplasmic
and external K+ concentration followed by addition of
bacterial suspension with either peptide, polymyxin B
or gentamicin sulphate to optiplate 96-well white
plates (Fisher Scientific) for concentrations ranging
from 10 to 80 μM. The fluorescence intensity was
measured by using the Hidex Plate Chameleon V
(Lablogic Systems, Brandon FL) with an excitation
wavelength of 622 nm and emission wavelength of
670 nm.
Scanning and transmission electron microscopy analysis
(SEM and TEM)
SEM and TEM analyses of untreated- and TP359-
treated exponential-phase bacteria (1 × 109 CFU/mL)
were performed essentially as previously described [28].
Bacteria were exposed to approximately 4× MIC for 4 h
at 37 °C prior to analyses.
Peptide effect on essential genes of P. aeruginosa
To determine the effect of TP359 on P. aeruginosa genes
essential for viability, cellular metabolism, pathogenicity,
outer membrane biosynthesis and assembly (Table 1),
were analyzed using qRT-PCR under bacteriostatic and
bactericidal conditions. The bacteriostatic condition is in-
dicated by bacterial recovery after 18 h of TP359 treat-
ment, whereas at the bactericidal condition which causes
cell death; samples were treated for a shorter time, to
avoid complete cell death. P. aeruginosa at 1 × 105 CFU/
mL were exposed to 0.5× MIC of TP359 and grown for
18 h in a shaker incubator at 37 °C to evaluate the
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bacteriostatic effects of TP359. For the bactericidal condi-
tion, P. aeruginosa at 1 × 109 CFU/mL were exposed to 4×
MIC of TP359 and grown for 4 h, and subsequently for 10
and 30 mins to compare the effect at these time period to
the bacteriostatic 4 h treatment condition. Also, P. aerugi-
nosa at 1 × 109 CFU/mL were exposed to 4× MIC of gen-
tamicin and grown for 4 h for control. Total RNA samples
from both conditions were purified using an RNeasy Mini
kit (Qiagen, Valencia, CA), and quantified using a spectro-
photometer (Nanodrop 2000c, ThermoFisher Scientific, Wal-
tham, MA). The cDNA synthesis was carried out using the
Applied Biosystems High Capacity cDNA Reverse Tran-
scriptase Kit (Life Technologies). One microgram of RNA
was used to amplify selected key outer membrane biogenesis
(oprI, oprL, oprF, acpP, uppS and opr86), cell division (ftsA
and ftsZ) and virulence (ampR and lasR) genes of P. aerugi-
nosa using the Applied Biosystems ViiA 7TM real time PCR
system (Life Technologies). Primer pairs for each gene are
shown in Table 2. The amplification conditions used were
one cycle of initial denaturation at 95 °C for 2 min,
followed by 40 cycles of 95 °C for 15 s, 56 °C for 25 s and
72 °C for 30s. The relative changes in gene expression
were calculated using the equation: 2−ΔΔCT [33] where all
values were normalized with respect to mRNA levels of
the house-keeping gene, rpoD. Fold changes in mRNA
gene expression levels were calculated relative to un-
treated bacteria samples. Each real-time PCR assay was
performed in triplicate from three independent experi-
ments and the results are expressed as the mean ± SD.
Peptide effect on outer membrane protein expression
The outer membrane proteins (OMPs) were extracted using
a method described previously with slight modifications [34].
Briefly, 0.5 L of mucoid and non-mucoid P. aeruginosa (1 ×
109 CFU/mL) was either treated with TP359 (4× of MIC) or
left untreated (control) and were grown for 4 h, and centri-
fuged at 2000 × g (Sorvall ST 40R, ThermoFisher Scientific,
Waltham, MA) for 10 min. The cell pellets each from con-
trol and treated cultures were re-suspended in 800 μl of
100 mM TrisHCl lysis buffer (0.5 M sucrose, 0.5 mM EDTA,
pH 8.6) and 4.2 ml of 50 mM TrisHCl lysis buffer (pH 8.6)
containing 0.5 M sucrose, 0.5 mM EDTA and 2.5 mM
MgCl2) and incubated on ice for 15 mins, followed by centri-
fugation at 7000 g at 40 °C. The supernatant contained the
periplasmic fraction and the cell pellets were re-suspended in
20 mM TrisHCl (pH 8.6) containing 0.5 M sucrose, 0.5 mM
Table 2 Gene and primers used for qRT-PCR (sequence 5′→ 3′)












Table 1 Genes and product function
Gene Gene product Gene function Reference
oprI Outer membrane lipoprotein OprI Membrane intergrity [46]
oprF Structural outer membrane protein Structrual stability [44, 47]
oprL Peptidoglycan lipoprotein protein OprL Membrane integrity & biogenesis [46]
opr86 Outer membrane protein BamA Outer membrane protein assembly [48]
uppS Undecaprenyl pyrophosphate synthase Cell wall biogenesis [49]
acpP Acyl carrier protein Membrane biogenesis [50, 51]
ftsZ Cell division protein FtsZ Cell division [52, 53]
ftsA Cell division protein FtsA Cell division [52, 53]
ampR Transcriptional regulator AmpR Virulence [54, 55]
lasR Transcriptional regulator LasR Quorum sensing [56, 57]
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EDTA), followed by sonication on ice using a cycle of 40 %
amplitude, for 5 min, 120 W at a frequency of 20 kHz on a
Biologics Ultrasonic Homogenizer (Fischer scientific, USA).
The sonicated suspension was centrifuged for 10 min
at 7000 g at 40 °C to remove the cell debris, followed
by ultracentrifugation (Beckman coulter, USA) at
132,000 g at 40C for 1 h to separate cytoplasmic
protein fraction in the supernatant. The pellet was
then re-suspended in 15 ml of 20 mM TrisHCl
(pH 8.6) containing 1 % Sarkosyl and incubated for
30 min on ice and the ultracentrifugation step was
repeated. Upon ultracentrifugation, outer membrane
proteins were obtained as pellets and were re-
suspended in 20 mM TrisHCl (pH 7.2).
Statistical analysis




Characterization of TP359 revealed that it is rich in the
hydrophilic amino acid residue lysine, and has a net
charge of +4. Grand average hydropathy value of TP359
was −1.25, indicating its hydrophilic nature, and hence
its solubility in water. The TP359 peptide extends hydro-
philic amino acids arginine (Arg3), and lysine (Lys4 and
5) residues towards the sides, and Lys8 towards the bot-
tom (carboxyl end) (Fig. 1, a and b). The hydrophilic
amino acid Lys contributes the positive charge to the
peptide while Arg3, Lys4, Lys5 and Lys8 make it readily
soluble. The non-polar amino acids at the N- terminal
(aliphatic Met1 and Try2 aromatic amino acids) are
followed by a polar positively charged region (Arg3,
Lys4, Lys5). The C-terminal has positively charged polar
Lys8; the polar, hydrophilic patches are bridged by ali-
phatic non-polar Ala6 and Leu7 residues. The polar and
non-polar features (prominently polar) and the three-
Fig. 1 In silico analysis of TP359 a Structure of TP359; b three-dimensional structure and surface development of the peptide. The amino acids
are represented as per the hydrophobicity; c electrostatic influence of the peptide (top and side view) shown in blue (positive charge)
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dimensional structure analyses show that the peptide
may possess the ability to penetrate the cell membrane.
TP359 is bactericidal against P. aeruginosa
Our results show that TP359 was highly effective in pre-
venting the growth of P. aeruginosa. The peptide exhib-
ited MICs as low as 4 and 8 μg/mL and MBCs of 16 and
64 μg/mL, respectively against the mucoid and non-
mucoid strains of P. aeruginosa. These values are con-
sistent with the MIC range of another cationic peptide,
EC5 for a different strain of P. aeruginosa (ATCC27835)
[35]. The positive controls, polymyxin B and gentamicin
sulphate displayed MICs between 0.25 and 0.5 μg/mL
(Table 3). Time-kill studies were performed to determine
the time-frame required for the effective killing of P.
aeruginosa by TP359. Our results showed a ≥3 log CFU/
mL within 8 h at 4× the MIC and a 5-log reduction of
the viable cell count within 2 h at 8× MIC for the mu-
coid strain (Fig. 2 a). Also for the non-mucoid strain, the
viable cell count decreased by ≥3 log CFU/mL within
3 h at 8× MIC (Fig. 2 b). These results demonstrate that
TP359 is bactericidal against P. aeruginosa and that its
bactericidal activity is dose- and time-dependent.
Cytotoxic activity
Given the potential consideration of TP359 as a thera-
peutic agent against P. aeruginosa, it was necessary to




Gentamicin sulphate 0.5/0.5 0.25/0.25
Polymyxin B 0.5/0.5 0.5/0.5
MIC minimum inhibitory concentration, MBC minimum
bactericidal concentration
Fig. 2 Time kill assay. Time kill assay of the mucoid (a) and non-mucoid (b) strains of P. aeruginosa. Killing was tested by incubating P. aeruginosa
with peptide concentrations at the MIC, three dilutions above (2×, 4× and 8× MIC) and one dilution below the MIC (0.5× MIC) in CA-MHB. Viable
cell counts were determined after 2, 4, 8 and 24 h of incubation at 37 °C. The growth control had no antibiotic. This data is a representative of
three separate experiments and significance was established at *P < 0.05 and **P < 0.01
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examine its toxicity to the human-lung carcinoma epi-
thelial A549 and mouse J774 macrophage cell lines. Our
results revealed that none of the tested concentrations
(0–200 μg/mL) had toxic effects against A549 cells over
a 48 h-time-frame (Fig. 3 a). TP359 was nontoxic to
J774 macrophages at lower concentrations but at higher
concentrations cells remained viable up to 85 % (200 μg/
mL at 24 h) and (100–200 μg/mL at 48 h) (Fig. 3 b).
Overall, our data suggest the safety of the peptide for
potential in vivo studies.
Membrane permeabilization
To begin to understand the antimicrobial mechanisms
of TP359, membrane permeabilization was studied using
the LIVE/DEAD stain kit, consisting of the SYTO9 and
propidium iodide (PI) dyes. The SYTO9 labeled all cells
(intact and permeabilized/damage membrane) green,
while only damaged membranes were labelled red by PI.
The percentage of cells with damaged membranes was
then calculated relative to the total number of cells at
different spots in different samples (Fig. 4 a – f ). These
data showed that TP359 is effective at permeabilizing
the membranes of both strains, as the percentages of
damaged membranes for both strains were ≥80 % for the
treated samples, in contrast to ≤20 % for the untreated
samples.
Membrane depolarization
Since results from membrane permeabilization assay in-
dicate OM permeabilization, we sought to investigate if
there is a breach of the permeability of the cytoplasmic
membrane. This was performed using the DiSC3(5) dye
Fig. 3 Cytotoxicity of peptide TP359. Human lung carcinoma epithelial A549 cells (a), and mouse J774 macrophages cells (b) were seeded in 96
well microtiter plates, and allowed to attach overnight before being exposed to the various peptide concentrations (0–200 μg/mL) for 24 and
48 h. Fifteen microliter of MTT dye were then added to each well and plates were subsequently incubated for 4 h before adding 100 μL of the
solubilizing/stop solution and read at a wavelength of 570 nm. This data is a representative of three separate experiments and significance was
established at *P < 0.05 and **P < 0.01
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which crosses the outer membrane of the bacterial cells
and concentrates at the cytoplasmic membrane. Upon
addition of membrane permealization agent, the dye is
released into the surrounding medium, and the fluores-
cence intensity is measured relative to the amount of
dye released. TP359 induced membrane depolarization
in both strains at 10 to 80 μM was evidenced by the re-
lease of the dye. The positive polymyxin B control also
induced membrane depolarization at those concentra-
tions, while the negative gentamicin control failed to in-
duce membrane depolarization (Fig. 5). These data show
that TP359 depolarized the cytoplasmic membrane of P.
aeruginosa, which may lead to cytoplasmic membrane
damage and killing of bacteria.
TP359 induced structural changes and damage to the
membrane of P. aeruginosa
We next used electron microscopy to begin to understand
how TP359 kills P. aeruginosa. Our SEM images revealed
that the TP359-treated mucoid cell population had punc-
tured membranes, efflux of intracellular material, as well
as disintegrated and agglomerated cells. Ruptured cell
debris was also evident (Fig. 6, b, c), while bacteria without
TP359 had smooth cell morphology (Fig. 6, a). The non-
mucoid TP359-treated cell population also showed similar
changes; cells were disintegrated, with evidence of dam-
ages on the membrane (Fig. 6, e, f ) as compared to the un-
treated cells (Fig. 6, d). TEM similarly showed treated cells
with compromised membranes and efflux of cytoplasmic
contents proceeding into ghost cells (Fig. 7). Both SEM
and TEM results established a possible mechanism of ac-
tion, whereby TP359 interacts with the cell membrane
causing membrane permeabilization and degradation,
with resulting changes in cell morphology. These results
indicate that TP359 caused loss of membrane structure
resulting in morphological changes and cell death.
TP359 effect on essential genes and protein expression of
P. aeruginosa
Selected critical genes involved in outer membrane bio-
genesis, peptidoglycan synthesis, cell division and viru-
lence were analyzed to determine the molecular effect of
Fig. 4 Membrane permealization. P. aeruginosa cells were exposed to 4× MIC of TP359 for 4 h. Cultures were centrifuged at 2000 × g for 10 min,
pellets were washed, incubated and re-suspended in 0.85 % NaCl. Cells were then incubated in the dark for 45 min in a 2× stock solution of the
baclight staining reagent before fluorescence was captured by the Nikon Eclipse TE200. a and d show untreated mucoid and non-mucoid P.
aeruginosa, respectively; b and e show TP359 treated mucoid and non-mucoid P. aeruginosa, respectively. Images are representatives of separate
experiments. For c and f random portions were selected for both treated and untreated samples using the NIS element 3.1 software and counted
before extrapolating the percentage of damaged membranes in the mucoid and non-mucoid strains of P. aeruginosa, respectively. This data is a
representative of three separate experiments and significance was established at *P < 0.05 and **P < 0.01
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TP359 against both strains of P. aeruginosa (Fig. 8). As
shown, TP359 did not significantly alter expression of
genes associated with cell division (ftsA and ftsZ) or viru-
lence (ampR and lasR) under either bacteriostatic or bac-
tericidal concentrations (Fig. 8, b and d). Contrastingly,
TP359 perturbed the expression of P. aeruginosa mem-
brane genes (oprL, oprI, oprF, acpP and uppS) under bac-
teriostatic or bactericidal concentrations (Fig. 8, b and d).
Most notably, under bacteriostatic concentrations there
was marked upregulation of the oprI gene (~10-fold) that
is essential for membrane integrity in mucoid and non-
mucoid strains. Examinations of the genes perturbed
under bactericidal concentrations revealed a consistent
and significant down-regulation of the oprI and oprF genes
(Fig. 8, a and c). As shown, there was a 5-fold decrease in
the expression of the oprI gene for both strains. However,
the most notable effect of TP359 was on the oprF gene
(essential for membrane integrity, bacterial shape, and
virulence [36]), where a significant 10- and 5-fold reduc-
tions in its expression was observed for the mucoid and
non-mucoid strains, respectively. This important finding
shows the effect of TP359 on the oprF gene, which may
suggest that disruption of membrane integrity, could con-
tribute to bacterial cell death. Moreover, this result
strongly supports the findings of the SEM and TEM ana-
lysis, where TP359-treated cells show flaccid membranes,
compared to the untreated control cells. Additionally, P.
aeruginosa exposed to TP359 for 10 and 30 mins showed
no significant changes when compared to the untreated,
indicating that a longer period of treatment was required
Fig. 5 Membrane depolarization. Exponential phase bacteria of a mucoid P. aeruginosa and b non-mucoid P. aeruginosa were incubated in
0.4 mM DiSC3 (5). Bacterial suspensions and either peptide, polymyxin B or gentamicin sulphate were added to Optiplate 96-well to obtain a
series of concentrations ranging from 10 to 80 μM. Fluorescence intensity was measured at baseline (Fi) and after 30 min of incubation (Ff).
Increase in fluorescence intensity was then obtained by subtracting the Fi from Ff.. This experiment was carried out in triplicate and significance
was established at *P < 0.05 and **P < 0.01
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to evaluate TP359 effect on these genes (Additional file 1:
Figure S1). Also, P. aeruginosa exposed to gentamicin
showed no significant changes when compared to the
TP359 treated samples, suggesting that TP359 effect was
not merely due to stress (Additional file 2: Figure S2).
We confirmed the effect of the peptide on outer mem-
brane proteins by analyzing outer membrane protein
fractions of TP359-treated P. aeruginosa using the
ExperionTM automated electrophoresis system (Fig. 9 a)
followed by semi-quantification of proteins (Fig. 9 b and
c). As shown in Fig. 9 a, there was a fully expressed
37.6 kDa OprF protein in both untreated mucoid and
non-mucoid P. aeruginosa samples. In contrast, expres-
sion was visually absent in the TP359-treated mucoid
strain and reduced in the TP359-treated non-mucoid
strain samples. This data correlated with our gene ex-
pression analysis, where a significant down-regulation of
the oprF gene was observed for both strains of P. aerugi-
nosa. The OprL protein expression also was significantly
reduced in the TP359-treated samples as compared to
the untreated samples for the mucoid (Fig. 9 a and b)
but not the non-mucoid strain (Fig. 9 a and c), which is
congruent with the gene expression results. The OprI,
with molecular weight less than 10 KDa was undetect-
able because its size is below the detection limit for the
ExperionTM automated electrophoresis system.
Discussion
The antimicrobial activity and molecular effects of a
novel proprietary cationic peptide, TP359 were investi-
gated independently against a mucoid and a non-mucoid
strain of P. aeruginosa. Our results revealed the follow-
ing: (i) both strains of P. aeruginosa were sensitive to
TP359, (ii) TP359 showed no toxic effects against hu-
man lung epithelial A549 and mouse J774 macrophage
cell lines, (iii) TP359 caused membrane damage, as
shown by SEM, TEM, LIVE/DEAD stain and membrane
depolarization assay and (iv) TP359 down-regulated P.
aeruginosa membrane biogenesis and peptidoglycan syn-
thesis associated genes.
TP359 exhibited antimicrobial activity against both
strains of P. aeruginosa at MIC concentrations, which
is in agreement with most cationic AMPs [35, 37],
with comparatively lesser effect on Gram-positive
strains. It was essentially non-toxic to eukaryotic cells,
which is also in agreement with other AMPs [38–40].
Fig. 6 Scanning electron microscopy (SEM). TP359- treated and untreated mucoid and non-mucoid strains of P. aeruginosa, exposed to 4 × MIC
of peptide and grown for 4 h, fixed in glutaraldehyde/paraformaldehyde, treated with osmium tetroxide, dehydrated in increasing concentrations
of ethanol, and sputter coated before SEM. Panels a and d show images of untreated mucoid and non-mucoid cells respectively. Bacterial cells
have intact cell membranes with uniform shape, while panels b and c show ruptured cells, with debris evident in peptide treated mucoid cells,
and panels e and f show peptide treated non-mucoid bacterial cells. Treated samples show cell disintegration (green and red arrows), pores on
cell membranes, upturned cells (orange arrows), and eruption of intra-cellular materials (blue arrows)
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Fig. 8 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). P. aeruginosa at 1 × 105 CFU/mL and 1 × 109 CFU/mL were either
untreated for control, or treated with 0.5× and 4× the MIC of TP359 and then grown for 18 and 4 h, representing bacteriostatic and bactericidal
concentrations, respectively. Total RNA was extracted, quantified before cDNA synthesis using reverse transcriptase, followed by PCR amplification.
Data obtained from three-independent experiments were used to analyze the relative gene expression by the 2-ΔΔCt method. Panels a and c
show the mucoid and non-mucoid strains for the bactericidal concentration and panels b and d for the bacteriostatic concentration
Fig. 7 Transmission electron microscopy (TEM). P. aeruginosa were exposed to 4× MIC of peptide and grown for 4 h, fixed in glutaraldehyde/
paraformaldehyde, treated with osmium tetroxide, dehydrated in increasing concentrations of ethanol, passed through propylene oxide, infiltrated
with resin, and ultrathin sections were collected and stained with uranyl acetate and lead citrate as described in the materials and methods section.
Panels a and d show images of untreated mucoid and non-mucoid cells, respectively, with intact cell membranes. Panel b shows peptide-treated
mucoid cells with cell membrane degradation and efflux of cellular material (red arrows); panel c shows empty cells with intracellular
material completely leaked out (blue arrow). Panel e shows peptide-treated non-mucoid bacterial cells with leaking intracellular material
(orange arrow) and panel f shows cell membrane degradation (purple arrow)
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The lack of toxicity of AMPs to eukaryotic cells may
be due to their membrane composition, which con-
sists of zwitterionic phospholipids that are neutral in
net charge [6]. This neutral charge reduces electro-
static interaction between the eukaryotic cell mem-
brane and AMPs, thus increasing their potential for
use as antipseudomonal drugs. Our investigation into
the effect of TP359 on the membrane of P. aerugi-
nosa revealed that TP359 caused outer membrane
permeabilization, which was further illustrated in the
TP359 sensitivity assay, where bacterial cells were
sensitive to TP359 (data not shown), suggesting its
effect on cell membrane integrity. Generally, the
antimicrobial activity of AMPs is mostly attributed to
membrane dysfunction, and cationic amphiphilic
AMPs are electrostatic, which makes them attracted
to the negatively charged bacteria membrane surfaces
[13, 26] causing membrane damage. Results from our
SEM and TEM analyses further confirm this, together
with the leaking of cytoplasmic content. These obser-
vations suggest that TP359 may penetrate the bacter-
ial membrane by electrostatic interaction between
TP359 and the bacterial cell surface.
Although the classic mechanism of action of AMPs
is their ability to cause membrane damage, other
mechanisms involve the inhibition of cell wall
Fig. 9 Evaluation of outer membrane proteins of TP359 –treated and untreated P. aeruginosa. P. aeruginosa at 1 × 109 CFU/mL were either
untreated for control, or treated with 4× the MIC of TP359 and grown for 4 h. The OMP fraction was extracted and then separated on the
ExperionTM Pro260 automated electrophoresis system for analysis. Panel a show the protein concentrations of OprF and OprL (as analyzed by
the automated system) and b and c represent the mucoid and non-mucoid strains respectively
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biogenesis, such as the lantibiotics-class 1 bacterio-
cins, Lcn 972, a class 2 bacteriocin and nicin [41].
Another class of peptides which target cell wall bio-
genesis is the class of endogenous host defense pep-
tides (HDP) such as the defensins and cathelicidins
[42]. Some reports also indicate that membrane per-
turbation alone may not be sufficient to elicit bacter-
ial cell death [8, 43], so we investigated the molecular
effect of TP359 against selected critical genes involved
in membrane biogenesis, peptidoglycan synthesis asso-
ciated genes, cell division genes and virulence genes.
Analysis of TP359-treated cells showed that the tran-
scriptional expression levels of some outer membrane
genes were down-regulated at bactericidal concentra-
tions, whereas they were up-regulated at bacteriostatic
concentrations in both strains. The most significantly
down-regulated gene in both strains at bactericidal con-
centrations was oprF, which encodes a major structural
and outer membrane porin (OprF). The reduced transla-
tional expression of OprF further underscores its dysreg-
ulation by TP359. P. aeruginosa OprF is essential for cell
shape, maintenance of peptidoglycan association and
structural integrity [44] and also for complete virulence.
Therefore, a down-regulation of OprF expression, sug-
gests a disruption in the outer membrane of the bacterial
cell, which could result into a permeable membrane for
foreign materials and water, leading to osmosis and cell
lysis. This effect of the peptide on oprF expression in-
deed correlates with our SEM analysis, where TP359-
treated cells had a rough shape compared to the
Fig. 10 Proposed mechanism of action of TP359. The proposed mechanism of action involves the interaction of the cationic TP359 with the
outer membrane of P. aeruginosa, which is negatively charged due to lipopolysaccharide (LPS), causing membrane permeabilization and
depolarization. This causes pores on the membrane resulting in efflux of cytoplasmic content to produce ghost cells. Furthermore, TP359 also
caused down-regulation of outer membrane associated genes such as the acpP, oprL, oprI and most importantly the oprF. The protein products,
AcpP, OprL, OprI and OprF are essential for fatty acid biosynthesis, transport of small molecules and structural membrane integrity. The effect of
TP359 on the oprF gene may disrupt its product, the OprF, which encodes membrane integrity and structure, leading to a compromised membrane
and ultimately cell death
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untreated cells, indicating defective bacteria membrane
integrity. The significance of our findings is further ac-
centuated by the observation that oprF mutants formed
poor anaerobic biofilms in the lung of CF patients, and
that lung secretions from CF patients with chronic P.
aeruginosa infection have increased antibodies to OprF
[45], indicating the significance of OprF for persistent
infection. Hence, based on our findings, we could infer
that TP359 could disrupt the cellular integrity of P. aer-
uginosa and increase clearance from CF airways. As a
positive control, the effect of gentamicin on the outer
membrane genes was investigated at both bactericidal
and bacteriostatic condition. Although some of the genes
were downregulated in both treated strains, they were
not statistically significant, suggesting that the effect of
TP359 on these genes may not be due to stress and
could be a contributory factor to its antimicrobial
activity.
To our knowledge, our study is the first to compre-
hensively characterize the antimicrobial effect of a
cationic AMP at the gene level. Based on the novelty of
our findings, we propose the possible mechanisms of
action of the TP359 peptide (Fig. 10) which may include:
i) direct contact with the bacterial cell surface due to
the attraction between the negatively charged bacterial
membrane and the positively charged peptide ii)
permeabilization of the outer membrane either due to
the downregulation of the outer membrane gene oprF,
which is essential for maintaining membrane integrity
and shape; or the presence of the hydrophilic portion of
the peptide, in the hydrophobic rich portion of the
bacterial membrane resulting in membrane instability, in
addition to other outer membrane biogenesis genes and
iii) inner membrane depolarization, through the dis-
placement of membrane charges.
Conclusion
Our novel cationic peptide TP359 showed antibacterial
activity against both strains of P. aeruginosa. TP359 also
induced significant morphological changes, and reduced
expression of outer membranes and peptidoglycan asso-
ciated genes specifically the oprF gene, suggesting that
the oprF gene could be a target for antimicrobial drug
development. Since the use of polymyxin B to treat P.
aeruginosa has been abandoned due to its nephrotox-
icity, TP359, which showed low cytotoxicity in vitro,
may prove to be a valuable therapeutic alternative, espe-
cially for CF patients. Further studies would include the
study of other cationic AMPs and verification of their
effect on outer membrane biogenesis genes, which could
enhance targeted antimicrobial effects. These could lead
to in vivo investigations of the antimicrobial activity of
TP359.
Additional files
Additional file 1: Figure S1. Differential gene expression levels of
selected genes for the mucoid and non-mucoid strains of P. aeruginosa
exposed to TP359 bactericidal treatment. P. aeruginosa at 1 × 109 CFU/mL
were either untreated as control, or treated with 4× the MIC of TP359
and then grown for 10 and 30 min. Total RNA was extracted, quantified
before cDNA synthesis using reverse transcriptase, followed by PCR
amplification. Data obtained from three-independent experiments
were used to analyze the relative gene expression by the 2-ΔΔCt
method. Panels A and B show the 10 and 30 min treatment for the
mucoid strain and non-mucoid strain, respectively. (JPG 145 kb)
Additional file 2: Figure S2. Differential gene expression levels of
selected genes for the mucoid and non-mucoid strains of P. aeruginosa
exposed to gentamicin bactericidal treatment. P. aeruginosa at 1 ×
109 CFU/mL were either untreated for control, or treated with 4× the
MIC of gentamicin and then grown for 4 h. Total RNA was extracted,
quantified before cDNA synthesis using reverse transcriptase, followed by
PCR amplification. Data obtained from three-independent experiments
were used to analyze the relative gene expression by the 2-ΔΔCt
method. Panels A and B show the gentamicin treatment for the mucoid
and non-mucoid strains of P. aeruginosa, respectively. (JPG 83 kb)
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